U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787429) titled 'Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma' on Aug. 19.
Brief Summary: Prospective, open, interventional, randomized, non-commercial trial
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Osteosarcoma
Intervention:
DRUG: Mifamurtide
Mifamurtide is a synthetic analog of muramyl dipeptide, which works by stimulating the immune system to destroy cancer cells. The exact mechanism of this activation in humans is unknown. The MEPACT product is a liposomal form of mifamurtide specifically formulated to reach macrophages in vivo...